News & Events

2005 Press Releases

Eidogen-Sertanty and Specs Release Kinase-Targeted Library

San Diego, CA (September 6, 2005) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, and Specs, a leading supplier of screening compounds and research chemicals, today announced the launch of a small molecule library focused toward inhibitors of several protein kinase families. This Kinase-Targeted Library represents the culmination of a co-marketing and collaborative service agreement between Eidogen-Sertanty and Specs.

Eidogen-Sertanty applied the Kinase Knowledgebase™ and eScreen® components of its DirectDesign™ discovery platform to select a subset of molecules from Specs' diverse compound collection. These selected molecules were predicted to have good bioavailability and activity against a series of therapeutically relevant kinases.

A subset of the Kinase-Targeted Library was experimentally validated through screening conducted at Memorial Sloan-Kettering Cancer Center against several of its in-house targets. Through Eidogen-Sertanty's in silico eScreen activity assessment and prioritization process, it was found that only a small percentage of compounds needed to be screened to observe a 5-fold increase in hit rate relative to the original primary screening data. "The eScreen data was overwhelmingly surprising to us, especially with respect to the observed enrichment in potential kinase inhibitors, which would have been missed otherwise," commented Dr. Hakim Djaballah, Head of Screening at Memorial Sloan Kettering Cancer Center in New York.

Under the terms of the co-marketing agreement, Specs will distribute the Kinase-Targeted Library to its worldwide customer base of pharmaceutical and biotechnology companies.

To inquire about purchasing the Specs/Eidogen-Sertanty Kinase-Targeted library, please contact Specs at

For more information, please contact:

Steve Muskal

About Eidogen-Sertanty, Inc.

Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit

About Specs

Specs is one of the world's leading suppliers of chemistry solutions for drug discovery to the Life Science industry. The main activities of Specs are focused on the supply of large numbers of high-quality screening compounds for High Throughput Screening (HTS), on-site and/or off-site compound handling, cheminformatics and contract research for lead discovery programs. Equipped with state-of-the-art technology and world-class expertise, Specs provides custom-tailored services and breakthrough solutions, allowing the customers to concentrate on the development of their core (research) activities. Information about Specs can be found at